Drug Trial Radar · NCT04871828
The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19)
Last checked: Nov 20, 2026Latest source record: May 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
66
Planned (sponsor's estimate)
Start
Feb 28, 2021
Primary completion
Sep 2021
Study completion Dec 2021
Sponsor
- Lead sponsor
- King Abdullah International Medical Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is an urgent need to explore therapeutic options for SARS-CoV-2 in order to face the pandemic. The selected intervention was based on that zafirlukast will have dual effect; first it will block the virus replication through inhibiting the COVID19 helicase that is involved in virus replication and secondly by reducing the inflammation through antagonizing the leukotriene receptor. The purpose of this study is to evaluate the clinical efficacy and safety of Leukotriene receptor antagonist in the treatment of moderate cases of COVID-19 patients.
Conditions
- Moderate Covid19
Interventions
Leukotriene Receptor AntagonistDrug
Zafirlukast
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to clinical improvement,Time frame: 28Day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
King Abdulaziz Medical city, MNGHA
Riyadh, Saudi Arabia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.